We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Diabetics Should Be Prioritized for Bariatric Surgery

By HospiMedica International staff writers
Posted on 27 Sep 2015
A new study suggests that the overall healthcare costs for obese patients with type 2 diabetes indicate they should be prioritized for obesity surgery. More...


Researcher at the University of Gothenburg (Sweden), Karolinska Institutet (Solna, Sweden), and other institutions conducted a prospective study to examine the long-term effect of bariatric surgery on healthcare costs, if obese patients were classified according to their diabetes status, rather than their body-mass index (BMI). The study included 2,010 adults participating in the Swedish Obese Subjects (SOS) study who underwent bariatric surgery at 25 Swedish surgical departments and 480 primary health-care centers between 1987 and 2001.

The results showed that the accumulated drug costs over the 15 year period did not differ between the surgery and control group in patients without diabetes at the time of surgery, but were on average USD 3,329 lower in surgery patients who had prediabetes and USD 5,487 per patient with diabetes. Hospital costs, however, were higher in all the patients who underwent surgery, but no differences in outpatient costs were observed.

When compared with patients treated conventionally, total healthcare costs—surgery, inpatient and outpatient hospital care, and prescription drugs—were higher in surgery patients who did not have diabetes at the beginning of the study (by USD 22,390 per patient) or who had prediabetes (USD 26,292), but not in patients with diabetes. The researchers surmised that it was most likely because the remission of diabetes that often occurs after bariatric surgery means that patients need fewer diabetes medications and hospital appointments in the subsequent years. The study was published on September 17, 2015, in the Lancet Diabetes & Endocrinology.

“We show that for obese patients with type 2 diabetes, the upfront costs of bariatric surgery seem to be largely offset by prevention of future health-care and drug use,” said study coauthor Martin Neovius, MD of the Karolinska Institutet. “This finding of cost neutrality is seldom noted for health-care interventions, nor is it a requirement of funding in most settings. Bariatric surgery should be held to the same economic standards as other medical interventions.”

The growing global epidemic of obesity and the lack of effective long-term dietary modification options make it likely that surgical treatment will become increasingly common for obesity, and that more diabetic patients will be initiating discussions with their primary care physicians regarding the benefits and risks of such procedures.

Related Links:

University of Gothenburg
Karolinska Institutet



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.